Skip to main content
Premium Trial:

Request an Annual Quote

Signal Genetics Increases IPO Target to up to $12.1M

NEW YORK (GenomeWeb) – Signal Genetics raised the target amount from its proposed initial public offering to up to $12.1 million.

In an amended Form S-1 filed with the US Securities and Exchange Commission on Friday, the company said it plans to offer 1.15 million shares of its common stock in its IPO at a range of $10 to $12 per share. At the midrange price of $11 the offering would bring in net proceeds of $10.3 million. If the underwriters exercise their overallotment option in full, that figure would rise to $12.1 million.

When Signal filed its Form S-1 in March, it said that it was targeting a raise of up to $25 million from its planned IPO. Last month it lowered the target amount to up to $9.3 million. The amount of shares that would be offered was also lowered to 909,090 shares in May from 2.3 million shares the company said in March that it would offer.

Signal plans to list its shares on the Nasdaq Capital Market under ticker symbol "SGNL." The underwriter on the offering is Aegis Capital.

The New York City-based firm offers the Myeloma Prognostic Risk Signature (MyPRS) test for asymptomatic monoclonal gammopathies. MyPRS is a microarray-based gene expression profile assay that predicts risk of early relapse, enabling physicians to stratify their patients and treatment options and identify genomic alterations that may affect which therapies doctors choose.

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.